New theranostic treatments exist for prostate cancer using prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PRLT) and neuroendocrine tumors with peptide receptor radionuclide therapy (PRRT).47,48. Here, FOLH1 is linked to neuroendocrine neoplasm.